Effects of an HMG-CoA reductase inhibitor in combination with an ACE inhibitor or angiotensin II type 1 receptor antagonist on myocardial metabolism in ischemic rabbit hearts

Hypertension Research

Volumn 25, Issue 2, 2002, Pages 203-210

  Kawabata, Hitoshi ^a   Nakagawa, Kizuku ^a   Ishikawa, Kinji ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin II receptor antagonist; Cardioprotection; HMG CoA reductase inhibitor; Ischemia

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHATE; PRAVASTATIN; TEMOCAPRILAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PH; CONTROLLED STUDY; DRUG EFFECT; ENERGY METABOLISM; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; ISOLATED HEART; MALE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; RABBIT;

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; CARDIOTONIC AGENTS; DRUG COMBINATIONS; ENZYME INHIBITORS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; PHOSPHATES; PRAVASTATIN; RABBITS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; TETRAZOLES; THIAZEPINES;

EID: 0036238159     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.25.203     Document Type: Article

References (47)

1. Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators
4. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
5. Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions
6. Neuroendocrine change in acute myocardial infarction
7. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor
8. Renin-angiotensin system inhibition in acute myocardial infarction in dogs: Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size
9. Effects of BIBR-277, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs
10. Angiotensin converting enzyme inhibitors and ischaemic heart disease
11. Relationships between structure and effects of ACE inhibitors: Comparative effects in myocardial ischaemia/reperfusion injury
12. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury
13. Effect of angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist on metabolism and contraction in ischemia-reperfused rabbit heart
14. Interactions among ACE, kinins and NO
15. Angiotensin II receptors: Protein and gene structures, expression and potential pathological involvements
16. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction
17. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats
18. 31P nuclear magnetic resonance analysis of metabolite concentrations in Langendorff-perfused rabbit hearts
19. Lethal myocardial ischemic injury
20. Improvement of nitric oxide-dependent vasodilation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation
21. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
22. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
23. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholestrolemic patients: A randomized, placebo-controlled, double-blind study
24. Cardioprotective activity of endogenous and exogenous nitric oxide on ischemia reperfusion injury in isolated guinea pig hearts
25. Protective role of nitric oxide synthase against ischemia-reperfusion injury in guinea pig myocardial mitochondria
26. Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size
27. Stress (heat shock) proteins: Molecular chaperones in cardiovascular biology and disease
28. Preconditioning of the ischaemic myocardium: Involvement of the L-arginine nitric oxide pathway
29. + channels induced by HMG CoA reductase inhibitor in ischemic rabbit heart
30. Angiotensin II receptors and angiotensin II receptor antagonists
31. Angiotensin receptors are implicated in the mechanism of mas action
32. The family of protein kinase C for signal transduction
33. Inositol, triphosphate, calcium, lithium, and cell signaling
34. Local inhibition of angiotensin II formation and bradykinin degradation in isolated hearts
35. Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin converting enzyme in ischemic hearts: Role of bradykinin and nitric oxide
36. Angiotensin II receptor antagonists: An emerging new class of cardiovascular therapeutics
37. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers
38. Effects of angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin II type 2 receptors
39. The functional role of angiotensin II-subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts
40. AT1 receptor blockade in experimental myocardial ischemia/reperfusion
41. Cardioprotection with angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist is not abolished by nitric oxide synthase inhibitor in ischemia-reperfused rabbit heart
42. + channels induced by angiotensin II type 1 receptor antagonist on metabolism, contraction and relaxation in ischemia-reperfused rabbit heart
43. Angiotensin II-forming pathways in normal and failing human hearts
44. Angiotensin and the failing heart
45. Marked species-difference in the vascular angiotensin II-formong pathways: Humans versus rodents
46. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II